基于浊毒理论论治非酒精性脂肪性肝病
|
摘要
目的:探讨浊毒理论在临床治疗非酒精性脂肪性肝病中的指导作用。方法:将157例非酒精性脂肪性肝病患者按随机数字表法分为观察组79例和对照组78例,观察组给予浊毒理论指导下的自拟柴胡祛脂汤联合中药茶饮治疗,对照组给予阿托伐他汀钙片,2组疗程均为12周,观察2组治疗前后肝功能(AST、ALT、TBiL)、血脂(TG、TC)、血液流变学(全血比黏度、红细胞压积、纤维蛋白原)及CT值的变化,并统计2组临床总有效率以及不良反应发生情况。结果:治疗12周后,观察组肝功能、血脂、血液流变学、CT值、临床总有效率及安全性均优于对照组,差异有统计学意义。结论:基于浊毒理论指导治疗非酒精性脂肪性肝病的疗效确切,可显著改善患者肝功能、血脂及血液流变学指标,显著改善肝脏形态与实质进而提高肝脏扫面后CT值,为治疗和研究非酒精性脂肪性肝病提供新思路,并进一步深化浊毒理论。
Objective: To explore the guiding role of Zhuodu theory in clinical treatment of non-alcoholic fatty liver disease. Methods: 157 cases of non-alcoholic fatty liver disease with phlegm and blood stasis were randomly divided into observation group( n = 79) and control group( n = 78). The observation group was treated with Chaihu Quzhi decoction combined with traditional Chinese medicine tea drink,the control group was treated with Atto vastatin calcium tablet for 12 weeks. Results: After 12 weeks of treatment,the liver function,blood lipid,hemorheology and CT value of the two groups were measured. The total clinical effective rate and safety were better than those of the control group,and the difference was statistically significant. Conclusion: Under the guidance of Zhuodu theory,the treatment of non-alcoholic fatty liver disease is effective,which can significantly improve the liver function,blood lipid and hemorheology,improve the shape and substance of the liver,and then improve the CT value of the liver after scanning. It not only provides a new idea for the treatment of non-alcoholic fatty liver disease,but also proves that the theory of turbid poison is scientific and advanced,which can promote the deepening and popularizing the theory of turbid toxin.
Objective: To explore the guiding role of Zhuodu theory in clinical treatment of non-alcoholic fatty liver disease. Methods: 157 cases of non-alcoholic fatty liver disease with phlegm and blood stasis were randomly divided into observation group( n = 79) and control group( n = 78). The observation group was treated with Chaihu Quzhi decoction combined with traditional Chinese medicine tea drink,the control group was treated with Atto vastatin calcium tablet for 12 weeks. Results: After 12 weeks of treatment,the liver function,blood lipid,hemorheology and CT value of the two groups were measured. The total clinical effective rate and safety were better than those of the control group,and the difference was statistically significant. Conclusion: Under the guidance of Zhuodu theory,the treatment of non-alcoholic fatty liver disease is effective,which can significantly improve the liver function,blood lipid and hemorheology,improve the shape and substance of the liver,and then improve the CT value of the liver after scanning. It not only provides a new idea for the treatment of non-alcoholic fatty liver disease,but also proves that the theory of turbid poison is scientific and advanced,which can promote the deepening and popularizing the theory of turbid toxin.
引文
[1]杨倩,刘勇涛,杜瑶,等.杨倩从浊毒论治非酒精性脂肪肝[J].辽宁中医杂志,2016,43(9):1845-1846.
[2]伊凡,马存贞,戴明,等.中药芪茵颗粒治疗非酒精性脂肪性肝病的临床疗效观察[J].新疆医科大学学报,2018,41(2):136-138.
[3]池肇春.非酒精性脂肪性肝病发病机制研究进展与现状[J].世界华人消化杂志,2017,25(8):670-683.
[4]杨倩,张云凤,才艳茹,等.从浊毒论治非酒精性脂肪肝[J].环球中医药,2016,9(11):1303-1305.
[5]郭泽淇,王倩怡,祁兴顺,等.《2017年美国肝病学会非酒精性脂肪性肝病诊疗指导》摘译[J].临床肝胆病杂志,2017,33(12):2275-2277.
[6]中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗专家共识意见[J].临床肝胆病杂志,2017,33(12):2270-2274.
[7]王正品,李佃贵,杜艳茹,等.浊毒致病论与现代中医病因学[J].中医杂志,2010,51(1):11-13.
[8]中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J].中医杂志,2017,58(19):1706-1710.
[9] MASARONEM,FEDERICOA,ABENAVOLIL,et al.Non alcoholicFatty liver:epidemiology and natural history[J].Rev Recent ClinTrials,2014,9(3):126-133.
[10]尤玉琴,陈文吟,孔祥平.阿托伐他汀治疗非酒精性脂肪性肝病的疗效观察[J].华南国防医学杂志,2011,25(6):494-497.
[11]常彬霞,李保森,邹正升.《2016年欧洲肝病学会、欧洲糖尿病学会和欧洲肥胖学会临床实践指南:非酒精性脂肪性肝病》摘译[J].临床肝胆病杂志,2016,32(8):1450-1454.
[12]毛宇湘.浊毒论[J].环球中医药,2012,5(7):520-522.
[13]黄世敬,王永炎.论血脂异常与浊毒[J].辽宁中医杂志,2016,43(1):65-67.
[2]伊凡,马存贞,戴明,等.中药芪茵颗粒治疗非酒精性脂肪性肝病的临床疗效观察[J].新疆医科大学学报,2018,41(2):136-138.
[3]池肇春.非酒精性脂肪性肝病发病机制研究进展与现状[J].世界华人消化杂志,2017,25(8):670-683.
[4]杨倩,张云凤,才艳茹,等.从浊毒论治非酒精性脂肪肝[J].环球中医药,2016,9(11):1303-1305.
[5]郭泽淇,王倩怡,祁兴顺,等.《2017年美国肝病学会非酒精性脂肪性肝病诊疗指导》摘译[J].临床肝胆病杂志,2017,33(12):2275-2277.
[6]中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗专家共识意见[J].临床肝胆病杂志,2017,33(12):2270-2274.
[7]王正品,李佃贵,杜艳茹,等.浊毒致病论与现代中医病因学[J].中医杂志,2010,51(1):11-13.
[8]中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J].中医杂志,2017,58(19):1706-1710.
[9] MASARONEM,FEDERICOA,ABENAVOLIL,et al.Non alcoholicFatty liver:epidemiology and natural history[J].Rev Recent ClinTrials,2014,9(3):126-133.
[10]尤玉琴,陈文吟,孔祥平.阿托伐他汀治疗非酒精性脂肪性肝病的疗效观察[J].华南国防医学杂志,2011,25(6):494-497.
[11]常彬霞,李保森,邹正升.《2016年欧洲肝病学会、欧洲糖尿病学会和欧洲肥胖学会临床实践指南:非酒精性脂肪性肝病》摘译[J].临床肝胆病杂志,2016,32(8):1450-1454.
[12]毛宇湘.浊毒论[J].环球中医药,2012,5(7):520-522.
[13]黄世敬,王永炎.论血脂异常与浊毒[J].辽宁中医杂志,2016,43(1):65-67.